Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-2281 and AD-2282 in Primary Hypercholesterolemia
NCT06747936Phase 3Completed
- Sponsor
- Addpharma, Inc.
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing AD-2281 + AD-2282 with AD-2281 + Placebo (2 arms). Primary endpoint: Change rate of LDL-C at 8 weeks. Started Feb 2025; status: completed.
02
Drugs
AD-2282
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06747936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747936.